Sangamo Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was $111.26 Mil.
During the past 12 months, Sangamo Therapeutics's average Total Assets Growth Rate was -17.70% per year.
During the past 3 years, the average Total Assets Growth Rate was -34.30% per year.
During the past 5 years, the average Total Assets Growth Rate was -10.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 28.70% per year.
During the past 13 years, Sangamo Therapeutics's highest 3-Year average Total Assets Growth Rate was 184.80%. The lowest was -60.30%. And the median was 10.30%.
The historical data trend for Sangamo Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sangamo Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics (NAS:SGMO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sangamo Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sangamo Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Sangamo Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGMO has been successfully added to your 